首页> 美国卫生研究院文献>American Journal of Clinical and Experimental Urology >Humanized mice for immune checkpoint blockade in human solid tumors
【2h】

Humanized mice for immune checkpoint blockade in human solid tumors

机译:人源化小鼠在人类实体瘤中的免疫检查点阻断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immunotherapy, specifically research involving immune checkpoint blockers (ICBs), has become a popular trend in anticancer research over the last three years. Due to the difficulties and often poor translation of results from models, models have become more relevant than ever. With the discovery of NOD, , and mutations, patient-derived xenograft (PDX) mouse models were developed, providing an ideal environment for ICBs testing. By implanting a PDX with either CD34 or peripheral blood mononuclear cells, we can create a human immune system capable of mounting a response against tumor burden. These animal models are currently being used to study molecular mechanisms, test drug efficacy, and trial drug combinations. Others have found use for these humanized mouse models as surrogates to represent otherwise uncommon diseases. Limitations remain with regards to what the models are capable of, but in the short amount of time between the development of these models and heightened interest in ICBs, these mice have already shown utility for future developments in the field of immunotherapy.
机译:免疫疗法,特别是涉及免疫检查点阻滞剂(ICB)的研究,在过去三年中已成为抗癌研究的流行趋势。由于存在困难,而且通常无法很好地转换模型的结果,因此模型变得比以往任何时候都更加重要。随着NOD和突变的发现,开发了患者源异种移植(PDX)小鼠模型,为ICBs测试提供了理想的环境。通过将CD34或外周血单核细胞植入PDX,我们可以创建能够增强针对肿瘤负担的反应的人类免疫系统。这些动物模型目前正用于研究分子机制,测试药物功效和试验药物组合。已发现其他人可将这些人源化小鼠模型用作替代品,以代表原本不常见的疾病。关于模型的功能仍然存在局限性,但是在开发这些模型与提高对ICB的兴趣之间的短时间内,这些小鼠已经显示出可用于免疫治疗领域的未来发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号